Cargando…
Screening for MAFLD: who, when and how?
Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent disease with increasing prevalence worldwide. Currently, no universal screening methods have been standardized, even when this disease poses a major health burden. MAFLD as a spectrum of diseases can range from simple steatosis,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869195/ https://www.ncbi.nlm.nih.gov/pubmed/36699945 http://dx.doi.org/10.1177/20420188221145650 |
_version_ | 1784876716655640576 |
---|---|
author | Pal, Shreya C. Méndez-Sánchez, Nahum |
author_facet | Pal, Shreya C. Méndez-Sánchez, Nahum |
author_sort | Pal, Shreya C. |
collection | PubMed |
description | Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent disease with increasing prevalence worldwide. Currently, no universal screening methods have been standardized, even when this disease poses a major health burden. MAFLD as a spectrum of diseases can range from simple steatosis, and steatohepatitis to fibrosis and hepatocellular carcinoma. Its extra-hepatic manifestations are vast and include cardiovascular diseases, extra-hepatic malignancies, cognitive and respiratory alterations. Given its extensive damage targets as well as its high prevalence, timely identification of the high-risk population presenting metabolic dysfunction should undergo universal non-invasive screening methods, which can be carried out through blood tests, easy and effective imaging techniques, such as ultrasound, score calculation and general clinical information brought together from primary patient–physician contact. |
format | Online Article Text |
id | pubmed-9869195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-98691952023-01-24 Screening for MAFLD: who, when and how? Pal, Shreya C. Méndez-Sánchez, Nahum Ther Adv Endocrinol Metab New Insights in MAFLD Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent disease with increasing prevalence worldwide. Currently, no universal screening methods have been standardized, even when this disease poses a major health burden. MAFLD as a spectrum of diseases can range from simple steatosis, and steatohepatitis to fibrosis and hepatocellular carcinoma. Its extra-hepatic manifestations are vast and include cardiovascular diseases, extra-hepatic malignancies, cognitive and respiratory alterations. Given its extensive damage targets as well as its high prevalence, timely identification of the high-risk population presenting metabolic dysfunction should undergo universal non-invasive screening methods, which can be carried out through blood tests, easy and effective imaging techniques, such as ultrasound, score calculation and general clinical information brought together from primary patient–physician contact. SAGE Publications 2023-01-21 /pmc/articles/PMC9869195/ /pubmed/36699945 http://dx.doi.org/10.1177/20420188221145650 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | New Insights in MAFLD Pal, Shreya C. Méndez-Sánchez, Nahum Screening for MAFLD: who, when and how? |
title | Screening for MAFLD: who, when and how? |
title_full | Screening for MAFLD: who, when and how? |
title_fullStr | Screening for MAFLD: who, when and how? |
title_full_unstemmed | Screening for MAFLD: who, when and how? |
title_short | Screening for MAFLD: who, when and how? |
title_sort | screening for mafld: who, when and how? |
topic | New Insights in MAFLD |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869195/ https://www.ncbi.nlm.nih.gov/pubmed/36699945 http://dx.doi.org/10.1177/20420188221145650 |
work_keys_str_mv | AT palshreyac screeningformafldwhowhenandhow AT mendezsancheznahum screeningformafldwhowhenandhow |